Highlights : Semaglutide has set a new standard for weight loss, with Wegovy often leading to 15% or more body weight reduction in clinical trials
Dermatitis and rash have been reported in 1% to less than 5% of patients receiving extended-release tramadol and allergic dermatitis, undefined hair disorder, and undefined skin disorder have been reported in less than 1% of patients
Novel therapies in diabetes: a comprehensive narrative review of GLP-1 receptor agonists, SGLT2 inhibitors, and beyond
52 Among patients undergoing bio-enteric IGB placement, the prevalence of hypertension, diabetes, hypercholesterolemia, and osteoarthropathy decreased from 29%, 15%, 32%, and 25% (pre-IGB), respectively, to 16%, 10%, 21%, and 13% at 3 years post-IGB removal